Eledon Pharmaceuticals Enacts Key Proposals and Board Changes

Eledon Pharmaceuticals (ELDN) just unveiled an announcement.

Eledon Pharmaceuticals, Inc. stockholders convened on July 10, 2024, approving key proposals that will shape the company’s future. They voted to increase the share cap of the 2020 Incentive Plan by 3.5 million and extend its duration by over a year. Additionally, Dr. Steven Perrin and Dr. June Lee were elected as Class I Directors, while KMJ Corbin & Company LLP was ratified as the independent accounting firm. Following Walter Ogier’s retirement, the board underwent a reshuffle, appointing new members to the Audit, Compensation, and Nominating and Corporate Governance Committees, ensuring compliance with Nasdaq’s independence standards.

For a thorough assessment of ELDN stock, go to TipRanks’ Stock Analysis page.